We’ve all heard that ‘food is good for your mood’. Now, a new study into mental health and nutrient supplementation has taken a leap forward by establishing the gold standard for which nutrients are proven to assist in the management of a range of mental health disorders.

As well as an established relationship between poor diet and mental illness, there is now a vast body of research examining the benefit of nutrient supplementation in people with mental disorders.

To unpack this research, an international team of scientists led by researchers at the University of Manchester and NICM Health Research Institute, Western Sydney University examined the ‘best of the best’ available evidence. The aim was to provide a clear overview of the benefit of specific nutrient supplements - including dosage, target symptoms, safety and tolerability - across different mental disorders.

The world’s largest review of top-tier evidence, published online today in World Psychiatry, examined 33 meta-analyses of randomised control trials (RCTs) and data from 10,951 people with mental health disorders including depression, stress and anxiety disorders, bipolar disorder, personality disorders, schizophrenia and attention-deficit/hyperactivity disorder (ADHD).

Although the majority of nutritional supplements assessed did not significantly improve mental health, the researchers found strong evidence that certain supplements are an effective additional treatment for some mental disorders, supportive of conventional treatment.

All nutrient supplements were found to be safe when recommended dosages and prescriptive instructions were adhered to and there was no evidence of serious adverse effects or contraindications with psychiatric medications.

Summary of results:The strongest evidence was found for omega-3 supplements (a polyunsaturated fatty acid) as an add-on treatment for major depression – reducing symptoms of depression beyond the effects of antidepressants alone.

• There was some evidence to suggest that omega-3 supplements may also have small benefits for ADHD.
• There was emerging evidence for the amino acid N-acetylcysteine as a useful adjunctive treatment in mood disorders and schizophrenia.
• Special types of folate supplements may be effective as add-on treatments for major depression and schizophrenia, however folic acid was ineffective.
• There was no strong evidence for omega-3 for schizophrenia or other mental health conditions.
• There is currently a lack of compelling evidence supporting the use of vitamins (such as E, C, or D) and minerals (zinc and magnesium) for any mental disorder.

Lead author of the study, Dr Joseph Firth, Honorary Research Fellow at The University of Manchester and Senior Research Fellow at NICM Health Research Institute, said the findings should be used to produce more evidence-based guidance on the usage of nutrient-based treatments for various mental health conditions.

“While there has been a longstanding interest in the use of nutrient supplements in the treatment of mental illness, the topic is often quite polarising, and surrounded by either over-hyped claims or undue cynicism,” Dr Firth said.

Senior author on the study, NICM Health Research Institute’s Professor Jerome Sarris said as the role of nutrition in mental health is becoming increasingly acknowledged, it was vital that an evidence-based approach be adopted.

“Future research should aim to determine which individuals might benefit most from evidence-based supplements and to better understand the underlying mechanisms so we can adopt a targeted approach to supplement use in mental health treatment.” Professor Sarris said. “The role of the gut microbiome in mental health is a rapidly emerging field of research, however more research is needed into the role of ‘psychobiotics’ in mental health treatment.”

The review involved researchers from Western Sydney University, King’s College London, The University of Manchester, The University of Queensland, ORYGEN National Centre of Excellence in Youth Mental Health, The University of Melbourne, University of Toronto and KU Leuven.

The research paper can be accessed in the October issue of World Psychiatry and online at http://doi.org/10.1002/wps.20672